S146 Evaluation of Engraftment and Diversity Following Open-Label Administration of CP101, an Investigational Oral Microbiome Therapeutic for the Prevention of Recurrent C. difficile Infection, in the PRISM-EXT Trial. (October 2022) - Kelly, Colleen; Fischer, Monika; Gerardin, Ylaine; Silva, Josh; Lau, Jennifer; Misra, Bharat; Borody, Thomas J.; Budree, Shrish; Khanna, Sahil